What is Vidarabin used for?

Vidarabin is indicated for Herpes simplex dendritic keratitis, Herpes simplex keratitis.

What development phase is Vidarabin in?

Vidarabin is FDA-approved (marketed).

What is the generic name of Vidarabin?

VIDARABINE is the generic (nonproprietary) name of Vidarabin.

Last reviewed 2026-04-20 · How we verify

Vidarabin (VIDARABINE)

FDA-approved approved Small molecule Quality 28/100

At a glance

Generic name	VIDARABINE
Drug class	vidarabine
Target	Dipeptidyl peptidase 4
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved
First approval	1976

Approved indications

Herpes simplex dendritic keratitis
Herpes simplex keratitis

Common side effects

No common side effects on file.

Key clinical trials

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (PHASE1)
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia (PHASE1)
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (PHASE1,PHASE2)
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer (PHASE1)
Two Step Haplo With Radiation Conditioning (PHASE2)
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (PHASE2)
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (PHASE1)
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vidarabin CI brief — competitive landscape report
Vidarabin updates RSS · CI watch RSS